Inhibiting the expression of ARID1B significantly reduces the proliferation, migration and invasive ability of bladder cancer cells, suggesting that it could serve as a potential prognostic biomarker for urothelial carcinoma of the bladder and aid in patient selection for adjuvant chemotherapy [22]. Here, ARID1B is linked to urinary bladder carcinoma.